

20  
77. The method as defined in Claim <sup>17</sup>73 wherein 50% of the glyburide particles are less than 23  $\mu$ m.

C'cont  
21  
78. The method as defined in Claim <sup>17</sup>73 wherein the glyburide has a particle size distribution of about 25% undersize value not more than 6  $\mu$ m, about 50% undersize value 7 to 10  $\mu$ m and about 75% undersize value not more than 23  $\mu$ m.

22  
79. The method as defined in Claim <sup>17</sup>73 wherein the starting daily dosage is 250 mg metformin/1.25 mg glyburide or 500 mg metformin/2.5 mg glyburide.

Remarks

In the parent application No. 09/460,920 filed December 14, 1999, an Amendment After Final Rejection mailed February 28, 2002 was filed and entered. However, the Examiner considered the Amendment but indicated that it did not place the application in condition for allowance because: "of the reasons given in Paper No. 11. Furthermore, the newly submitted IDS raises new issues that would require further consideration".

The IDS which was referred to above is the Supplemental Information Disclosure Statement mailed April 25, 2002, a copy of which is enclosed.


The present CPA has been filed to allow the Examiner the opportunity to reconsider the arguments presented in the Amendment After Final Rejection and to consider the references set out in the Supplemental Information Disclosure Statement mailed April 25, 2002 and the references cited in the accompanying Information Disclosure Statement.

New Claims 73 to 79 which correspond to previously cancelled Claims 61 to 67 (which are original Claims 25 to 31) have been added.

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-4336

Date: June 10, 2002

Respectfully submitted,

  
Burton Rodney  
Attorney for Applicant  
Reg. No. 22,076